[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564630":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":17,"locations":7,"responsibleParty":23,"collaborators":7,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":7,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":34,"phases":7,"briefSummary":35,"conditions":36,"keywords":7,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":43,"locationsCount":7},{"fullName":5,"class":6},"Regeneron Pharmaceuticals","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Dupilumab","Administered per protocol",[14,15,16],"REGN668","DUPIXENT®","SAR231893",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Requests for compassionate use must be initiated by a treating physician. Physicians should contact","CONTACT","844-734-6643","compassionateuserequests@regeneron.com",{"type":24,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100564630","expanded-access-of-dupilumab-in-adults-with-severe-immunoglobulin-e-ige-mediated-food-allergy-previously-treated-with-linvoseltamab-100564630",false,"NCT06631677","Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab","An Open Label, Expanded Access Program of Dupilumab in Adults With Severe IgE-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab","Key Inclusion Criteria\n\n1. Eligible participants for this program consist of adults who have completed the End of Study (EOS) visit in the parent phase 1 study, R5458-668-ALG-2219 (NCT06369467)\n2. Administration of first dose of EAP dupilumab occurs as defined in the protocol\n\nKey Exclusion Criteria\n\n1. Participants who, during the parent study (R5458-668-ALG-2219 \\[NCT06369467\\]), developed a Serious Adverse Event (SAE) and\u002For Adverse Event (AE) as defined in the protocol\n2. Any temporary discontinuation of study drug dupilumab lasting \\>2 weeks during the parent study R5458-668-ALG-2219 (NCT06369467)\n3. Greater than 2 weeks since last administration of study drug dupilumab from the parent study R5458-668-ALG-2219 (NCT06369467)\n\nNOTE: Other protocol defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years","EXPANDED_ACCESS","This is an expanded access program of dupilumab. The objective of the program is to provide continued dupilumab to adult participants with severe IgE-mediated food allergy who were previously treated with a short course of linvoseltamab and background dupilumab in the parent study R5458-668-ALG-2219 (NCT06369467).",[37],"Food Allergy","AVAILABLE","2026-06-23",{"date":41,"type":42},"2026-06-26","ACTUAL",{"name":5,"class":6}]